12 September 2016 - Scottish patients with a rare form of blood cancer have been granted access to a daily pill which could prolong their lives and reduce treatment side effects.

The SMC approved the drug dasatinib monohydrate for use on the NHS for adult patients with chronic myeloid leukaemia, an aggressive form of blood cancer which affects around 460 Scots. Patients north of the border will be the first in the UK to access the daily medication, which will allow many to live a more normal life as it offers a quicker response than existing treatments. The regulatory body also approved treatments for advanced skin cancer and blood clots.

Read The Scotsman article